 | |
| Clinical data | |
|---|---|
| Routes of administration | By mouth |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.020.627 |
| Chemical and physical data | |
| Formula | C18H25NO |
| Molar mass | 271.404 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Cyclazocine is a mixedopioidagonist/antagonist related todezocine,pentazocine andphenazocine. It is in thebenzomorphan andbenzazocine family of drugs.[1] It is aκ-opioid receptor agonist andμ-opioid receptorpartial agonist, and also has high affinity for theδ-opioid receptor.[2]
Research into the use of cyclazocine for the treatment ofbipolar patients with depression was undertaken by Fink and colleagues (1970). It showed that 8 out of 10 patients experienced moderate improvement.[citation needed]
Research during the 1960s and 1970s into the possible use of cyclazocine for management of pain, and later for assisting treatment of opioid addiction was severely hampered by the drug's psychotomimetic, dysphoric, and hallucinatory effects.[3] Thedysphoric/anxiety-inducing effects of the drug correlate with increasing dosage and would likely reduce the risk of abuse in the same manner as other opioids which preferentially act on theKOR versus theDOR andMOR, although the side-effect threshold is often lower than the lowest effective dose.